BCL2L10 Silencing in Gastric Cancer: A Common Feature in Early Carcinogenesis

Strategic Insights -

New research published in the journal Oncology Reports has shed light on the role of BCL2L10 in gastric cancer. The study, conducted by R. Mikata and colleagues at Chiba University, investigated the methylation status of BCL2L10 and its expression in gastric cancer tissues and corresponding non-neoplastic mucosae. The findings suggest that BCL2L10 is frequently silenced by promoter hypermethylation in gastric cancer, a common feature in the early steps of gastric carcinogenesis.

Key Takeaways:

  • BCL2L10 is a tumor suppressor gene that belongs to the pro-apoptotic Bcl-2 family, and its overexpression has been shown to cause apoptosis and growth inhibition of gastric cancer cells.
  • Aberrant methylation of BCL2L10 was detected in 38% of gastric cancer tissues and in 24% of corresponding non-neoplastic mucosae, correlating with low expression of BCL2L10.
  • Methylation of p16, RUNX3, and hMLH1 genes was found in gastric cancer tissues and in corresponding non-neoplastic mucosae at similar frequencies to previous reports.
  • Expression of EZH2, a gene associated with DNA methylation of its target genes, was detected more frequently in tumors (48%) compared to corresponding non-neoplastic mucosae (10%) (p=0.006).
  • The study suggests that silencing of BCL2L10 by aberrant methylation is a common feature in gastric cancer and may be involved in the early steps of gastric carcinogenesis.

Statistics:

  • 38% of gastric cancer tissues showed aberrant methylation of BCL2L10.
  • 24% of corresponding non-neoplastic mucosae showed aberrant methylation of BCL2L10.
  • Methylation of p16, RUNX3, and hMLH1 genes was found in gastric cancer tissues at frequencies similar to previous reports.
  • Expression of EZH2 was detected in 48% of tumors compared to 10% of corresponding non-neoplastic mucosae (p=0.006).

Sources:

  • R. Mikata et al., "BCL2L10 is frequently silenced by promoter hypermethylation in gastric cancer.," Oncology Reports, 2010;23(6):1701-8.